Raludotatug deruxtecan with or without bevacizumab for ovarian cancer that grew on PARP inhibitors
Tests raludotatug deruxtecan in adults with advanced ovarian cancer that grew during PARP inhibitor maintenance.
Key facts
- Who runs it
- Merck Sharp & Dohme LLC
- Where
- Burlington, Fort Worth, Fountain Valley, and Orlando, United StatesSee the 4 sitesAlso in 2 other countries, 3 sites
- Trial code
- NCT07743164
- EU 2025-525130-59-00
- U1111-1333-3042
- Registry title
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 646 people, planned
- Started
- 7 Oct 2026
- Expected to end
- 31 Aug 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- R-DXd
- Bevacizumab
- Carboplatin
- Paclitaxel
- Gemcitabine
- Pegylated liposomal doxorubicin (PLD)
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult women with advanced high-grade ovarian, peritoneal or fallopian tube cancer whose cancer grew during PARP-inhibitor maintenance treatment after first-line chemotherapy.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Advanced high-grade serous or high-grade endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer that is platinum-sensitive.
- Earlier treatment
- Must have had 1 line of platinum-based treatment with at least 4 cycles of platinum-doublet chemotherapy, then a PARP inhibitor (PARPi) as maintenance. The cancer must have grown on PARPi or within 42 days of the last dose.
Main reasons for not taking part
- Clear cell, mucinous or sarcomatous cancer, mixed tumors, or low-grade or borderline ovarian cancer
- History of blood clot disorders, bleeding, coughing up blood, or active stomach or bowel bleeding within 6 months before randomization
- Uncontrolled or significant heart or blood vessel disease
- Severe lung problems or lung disease
- Current bowel obstruction, or another cancer that is growing or needed treatment in the past 3 years
The registry criteria, word for word
Show all 13 criteriaShow less
Other criteria
- The main inclusion criteria include but are not limited to the following:
- Has a histologically or cytologically documented advanced high-grade serous or high-grade endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer
- Has received 1 line of platinum-based therapy with a minimum of 4 cycles of platinum-doublet chemotherapy and have platinum-sensitive disease
- Has received a poly (ADP-ribose) polymerase inhibitor (PARPi) as maintenance treatment after the first line platinum-based chemotherapy course and experienced radiographic progression during treatment or within 42 days of the last dose of PARPi
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days before randomization
- Has recovered from any AEs due to previous anticancer therapies; The main exclusion criteria include but are not limited to the following:
- Has clear cell, mucinous, or sarcomatous histology, mixed tumors containing any histology, or low-grade/borderline ovarian cancer
- Has a history of thrombotic disorders, hemorrhage, hemoptysis, or active GI bleeding within 6 months before randomization
- Has uncontrolled or significant cardiovascular disease
- Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of randomization, severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, pleural effusion) and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis), or prior pneumonectomy
- Has received chronic steroid treatment, with some exceptions
- Has current, clinically relevant bowel obstruction (including subocclusive disease) including obstruction related to underlying epithelial ovarian cancer, abdominal fistula or GI perforation, intra-abdominal abscess, or evidence of rectosigmoid involvement by pelvic exam
- Has known additional malignancy that is progressing or has required active treatment within the past 3 years
Where in United States
Also in 2 other countries, 3 sites
- Lahey Clinic (Site 0042)Burlington, United StatesContact: Study CoordinatorTaking people
- JPS Oncology and Infusion Center (Site 0019)Fort Worth, United StatesContact: Study CoordinatorTaking people
- MemorialCare Orange Coast Medical Center (Site 0032)Fountain Valley, United StatesContact: Study CoordinatorTaking people
- Orlando Health Cancer Institute (Site 0018)Orlando, United StatesContact: Study CoordinatorTaking people
About the trial
What the trial wants to find out
Researchers are looking for new ways to treat advanced, high-grade ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body (metastatic) and may not be removed with surgery. High-grade means the cancer cells grow and spread quickly. This trial includes types of OC that started in cells that cover the ovaries, in the lining of the belly, or in the fallopian tubes.
Read full original descriptionShow less
The usual treatment for high-grade OC may include one or both of these:
* Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing. * Bevacizumab, which is a targeted therapy that works to control how specific types of cancer cells grow and spread and targets tumor blood vessels.
Researchers want to learn about the trial medicine, raludotatug deruxtecan (also called R-DXd or MK-5909), when given with and without bevacizumab and how participants respond to it. R-DXd is an antibody drug conjugate (ADC). An ADC is a type of medicine that attaches to a specific target on cancer cells and delivers treatment to destroy those cells.
The goals of this trial are to learn if participants who receive R-DXd, with or without bevacizumab, live longer overall and without their cancer growing or spreading compared to those who receive usual treatment.
The 2 groups in the trial
- R-DXd +/- BevacizumabTreatment being tested
Participants will receive intravenous (IV) raludotatug deruxtecan (R-DXd) with or without IV bevacizumab for up to 2 years until progressive disease (PD), unacceptable toxicity, or other protocol-specified reason for discontinuation
Treatment: R-DXd and Bevacizumab
- Standard of CareExisting treatment, for comparison
Participants receive 6 to 8 cycles of investigator's choice of one of three options of platinum-based chemotherapy with or without IV bevacizumab. Bevacizumab treatment if elected, will continue until PD, unacceptable toxicity, or other protocol specified reason for discontinuation
Treatment: Bevacizumab, Carboplatin, Paclitaxel, Gemcitabine, and Pegylated liposomal doxorubicin (PLD)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Open-Label, Multicenter, Randomized Study of Raludotatug Deruxtecan (MK-5909, R-DXd) With or Without Bevacizumab Versus Standard-of-Care Platinum-Based Doublet Chemotherapy With or Without Bevacizumab in Participants With Advanced Platinum-Sensitive High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Progressed During First-Line PARPi Maintenance (ENGOT-ov107 / GOG-3142 / REJOICE-Ovarian05)
- Plain-language title
- Raludotatug deruxtecan with or without bevacizumab for ovarian cancer that grew on PARP inhibitorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 10 November 2026